MehmoodHussainHashmiMD

Oncology • Topeka, KS

Hematologic Oncology

Executive Director Oncology Service Line

Join to view full profile

Dr. Hashmi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Hashmi's full profile

Already have an account?

Office
1414 Sw 8th Ave
Topeka, KS 66606
Phone+1 785-354-5300

Fax+1 785-354-5309
Is this information wrong?

Education & Training

Carnegie Mellon UniversityMasters in Medical Management, 2018 - 2020
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2001 - 2004
Dow University of Health SciencesClass of 1998

Certifications & Licensure

OK State Medical License 2003 - 2024
KS State Medical License 2007 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer Start of enrollment: 2009 Jun 01
Active, not recruiting
Phase 2
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Start of enrollment: 2014 Oct 03
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasect...
Leonard J Appleman, Se Eun Kim, Wayne B Harris, Sumanta K Pal, Michael R Pins, Jill Kolesar, Neeraj Agarwal, Rahul A Parikh, Daniel A Vaena, Christopher W Ryan, Mehmoo...> ;Journal of Clinical Oncology. 2024 Mar 26
Impaired microvascular reactivity in patients treated with 5-fluorouracil chemotherapy regimens: Potential role of endothelial dysfunction.
Stephen T Hammond, Dryden R Baumfalk, Shannon K Parr, Alec L E Butenas, Britton C Scheuermann, Vanessa-Rose G Turpin, Bradley J Behnke, Mehmood H Hashmi, Carl J Ade> ;International Journal of Cardiology. Heart & Vasculature. 2023 Dec 1
5 citations
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Smita Mehta, James C. Moon, Mehmood Hashmi, Michael LeBlanc, Chao Hui Huang, Elizabeth Rinehart, Gregory T. Wolf, Susan G. Urba, Sushanta K. Banerjee, Stephen K. Willi...> ;Oncology Reports. 2013 Jun 1
59 citations
Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's...
Mehmood Hashmi, Peter J. Van Veldhuizen> ;Expert Opinion on Biological Therapy. 2010 Apr 12
Join now to see all

Press Mentions

Stormont Vail Cultural Ambassadors Uphold Small Moments Culture in HospitalsAugust 26th, 2020

Hospital Affiliations

The University of Kansas HospitalKansas City, Kansas
Stormont Vail HealthTopeka, Kansas